Merck Patent Gesellschaft MIT Beschrankter Haftung

Merck Patent Gmbh

Merck Patent Gesellschaft

Frank Weber

Christoph Seyfried

Gerd Bartoszyk

Hermann Russ

Henning Böttcher

Ralf M Devant

Maria Devant, Legal Representative

Rolf Wagenknecht

Ilona Taubert

Antonia Almeida

Herman Russ

Franz Zorn

Wilhelm Eberle

(R)-(&#x2212;)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane or a physiologically acceptable salt thereof is useful for treatment of adverse effects in treating Parkinson's disease.

Use of(R)-(&#x2212;) -2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts

(R/S)-(&#x2212;/+)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane or a physiologically acceptable salt thereof and/or (S)-(+)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane or a physiologically acceptable salt thereof are used for the manufacture of a medicament for the treatment of extrapyramidal movement disorders and/or adverse effects in extrapyramidal movement disorders.

Use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts

Compounds of formula I in which R has a meaning as indicated in claim, or one of their optical isomers or pharmaceutically acceptable salts, used for the treatment of extrapyramidal movement disorders and/or adverse effects in extrapyramidal movement disorders and/or for the treatment of extrapyramidal symptoms (EPS) induced by neuroleptics. 

Use of substituted aminomethyl chromans

Process for the production of spongiosa bone ceramic having low calcium

Growing community of inventors

Gross-Zimmern, Germany

Frank Weber